| Quarterly Financials | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 |
Revenue  | 395 | 443 | 288 | 406 | 449 | 589 |
| Expenses | 287 | 315 | 254 | 293 | 320 | 422 |
| EBITDA | 108 | 128 | 34 | 112 | 129 | 167 |
| Operating Profit % | 25 % | 28 % | 9 % | 26 % | 27 % | 27 % |
| Depreciation | 31 | 31 | 31 | 36 | 34 | 38 |
| Interest | 23 | 21 | 21 | 21 | 23 | 11 |
| Profit Before Tax | 53 | 76 | -18 | 55 | 72 | 119 |
| Tax | 13 | 20 | -5 | 14 | 18 | 31 |
| Net Profit | 40 | 56 | -14 | 42 | 54 | 88 |
| EPS in ₹ | 2.19 | 31.00 | 0.00 | 2.22 | 2.89 | 4.24 |
Sai Life Sciences
756.95
+40.30
(5.62%)
Market Cap
15,752.10 Cr
EPS
4.57
PE Ratio
92.89
Dividend Yield
0.00 %
Industry
Healthcare52 Week High
808.80
52 Week Low
636.10
PB Ratio
7.42
Debt to Equity
1.00
Sector
Pharmaceuticals
Investment Returns
In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from3 analysts
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,677.60 | #1 4,02,512.40 | 35.10 | #1 49,887.20 | 12.06 | #1 9,648 | -18.99 | 42.28 | |
6,612.00 | 1,75,527.80 | 80.12 | 8,184.00 | 0.89 | 1,600 | 23.05 | 63.47 | |
1,465.70 | 1,18,372.10 | 22.44 | 26,520.70 | 14.17 | 4,155 | 30.28 | 44.20 | |
3,174.70 | 1,07,446.30 | 55.71 | 10,785.70 | 11.59 | 1,656 | 10.91 | 44.55 | |
1,251.20 | 1,04,407.10 | #1 18.47 | 28,905.40 | 12.36 | 5,578 | 21.14 | 67.52 | |
2,467.70 | 1,01,812.00 | 51.37 | 10,615.60 | 19.57 | 1,942 | -10.91 | 48.86 | |
930.00 | 93,579.80 | 20.04 | 19,831.50 | 13.82 | 3,831 | -0.19 | 63.14 | |
1,957.70 | 89,377.00 | 27.25 | 20,141.50 | #1 19.94 | 1,936 | #1 112.49 | 43.05 | |
1,147.80 | 66,664.40 | 19.29 | 29,559.20 | 17.55 | 3,169 | -0.50 | 43.00 | |
30,455.00 | 64,714.70 | 45.75 | 6,097.20 | 10.80 | 1,201 | 27.83 | 50.48 |
Forecast
Actual
Growth Rate
Revenue Growth
20.01 %
Net Income Growth
728.00 %
Cash Flow Change
19.91 %
ROE
658.04 %
ROCE
94.05 %
EBITDA Margin (Avg.)
-
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2023 | 2024 |
| Total Assets | 2,187 | 2,275 |
| Fixed Assets | 1,037 | 1,180 |
| Current Assets | 964 | 945 |
| Capital Work in Progress | 151 | 107 |
| Investments | 2 | 2 |
| Other Assets | 997 | 987 |
| Total Liabilities | 2,187 | 2,275 |
| Current Liabilities | 759 | 740 |
| Non Current Liabilities | 540 | 560 |
| Total Equity | 888 | 975 |
| Reserve & Surplus | 870 | 957 |
| Share Capital | 18 | 18 |
Cash Flow
| Cash Flow | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| Net Cash Flow | 239 | -150 | -1 | 75 | -80 | -24 |
| Investing Activities | -158 | -262 | -260 | -102 | -99 | -191 |
| Operating Activities | 129 | 116 | -36 | 105 | 219 | 263 |
| Financing Activities | 268 | -4 | 296 | 72 | -201 | -95 |
Share Holding
| % Holding | Jul 2024 | Sept 2024 | Dec 2024 | Mar 2025 |
| Promoter | 39.64 % | 35.24 % | 35.24 % | 35.17 % |
| FIIs | 0.00 % | 7.64 % | 11.72 % | 12.36 % |
| DIIs | 0.00 % | 5.61 % | 11.95 % | 13.26 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 0.00 % | 18.68 % | 8.88 % | 7.69 % |
| Others | 60.36 % | 32.84 % | 32.22 % | 31.52 % |
| No of Share Holders | 70 | 5,72,970 | 82 | 1,40,677 |
Dividend History
Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
No dividends have been distributed by the company in the past 10 years
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 13 May 2025 |  Quarterly Result Announcement | NA | 13 May 2025 | 717.70 | 713.35 |
| 06 Feb 2025 | Quarterly Result Announcement | NA | 06 Feb 2025 | 695.75 | 694.80 |
Announcements
Compliances-Reg.24(A)-Annual Secretarial Compliance
4 days ago
4 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation4 days ago
4 days agoAnnouncement under Regulation 30 (LODR)-Allotment7 days ago
7 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation7 days ago
7 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation7 days ago
7 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation7 days ago
7 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation7 days ago
7 days agoAnnouncement under Regulation 30 (LODR)-Earnings Call Transcript9 days ago
9 days agoAnnouncement under Regulation 30 (LODR)-Newspaper PublicationMay 16, 2025
May 16, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 15, 2025
May 15, 2025Shareholder Meeting / Postal Ballot-Notice of Postal BallotMay 15, 2025
May 15, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 14, 2025
May 14, 2025Announcement under Regulation 30 (LODR)-Monitoring Agency ReportMay 14, 2025
May 14, 2025Announcement under Regulation 30 (LODR)-Investor PresentationMay 14, 2025
May 14, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 14, 2025
May 14, 2025Announcement under Regulation 30 (LODR)-AllotmentMay 14, 2025
May 14, 2025Approved Notice Of Postal BallotMay 14, 2025
May 14, 2025Announcement under Regulation 30 (LODR)-Change in ManagementMay 14, 2025
May 14, 2025Results- Financial Results For The Period Ending 31St March 2025May 14, 2025
May 14, 2025Board Meeting Outcome for Approval Of Financial Results For The Financial Year Ending 31.03.2025May 14, 2025
May 14, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 06, 2025
May 06, 2025Board Meeting Intimation for Notice Of Board MeetingMay 06, 2025
May 06, 2025Announcement under Regulation 30 (LODR)-Change in DirectorateApr 28, 2025
Apr 28, 2025Announcement under Regulation 30 (LODR)-Change in ManagementApr 23, 2025
Apr 23, 2025Announcement under Regulation 30 (LODR)-AllotmentApr 23, 2025
Apr 23, 2025Clarification On Increase In VolumeApr 16, 2025
Apr 16, 2025Clarification sought from Sai Life Sciences LtdApr 16, 2025
Apr 16, 2025Compliance Certificate For The Period Ending March 31 2025Apr 11, 2025
Apr 11, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 11, 2025
Apr 11, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 03, 2025
Apr 03, 2025This Is To Inform You That A Notice Of Demand Was Issued By The Income Tax Department On 26 March 2025 Raising A Demand U/S 156 Of The Income Tax Act 1961.Mar 27, 2025
Mar 27, 2025Announcement under Regulation 30 (LODR)-AllotmentMar 27, 2025
Mar 27, 2025Closure of Trading WindowMar 26, 2025
Mar 26, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 25, 2025
Mar 25, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 25, 2025
Mar 25, 2025Announcement under Regulation 30 (LODR)-AllotmentMar 24, 2025
Mar 24, 2025Announcement under Regulation 30 (LODR)-CessationMar 24, 2025
Mar 24, 2025Announcement under Regulation 30 (LODR)-Change in DirectorateMar 24, 2025
Mar 24, 2025Announcement under Regulation 30 (LODR)-AllotmentMar 20, 2025
Mar 20, 2025Reporting Of Violation Under The Code Of Conduct For Regulating Monitoring And Reporting Of Trading By Designated Persons And Their Immediate Relatives Of The Company (The Code) Under SEBI (Prohibition Of Insider Trading) Regulations 2015
Mar 20, 2025
Mar 20, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 18, 2025
Mar 18, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 18, 2025
Mar 18, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 18, 2025
Mar 18, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 13, 2025
Mar 13, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 13, 2025
Mar 13, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 13, 2025
Mar 13, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 13, 2025
Mar 13, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 13, 2025
Mar 13, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 13, 2025
Mar 13, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 13, 2025
Mar 13, 2025Technical Indicators
RSI(14)
Neutral 58.30
ATR(14)
Volatile 29.89
STOCH(9,6)
Neutral 32.28
STOCH RSI(14)
Neutral 35.90
MACD(12,26)
Bullish 0.16
ADX(14)
Weak Trend 21.34
UO(9)
Bearish 45.79
ROC(12)
Downtrend But Slowing Down -0.12
WillR(14)
Neutral -35.96
Mutual Fund Holdings
| Funding House | No of Shares | Current Holding % | 1M Change % | 3M Change % | Month | |
|---|---|---|---|---|---|---|
 Aditya Birla Sun Life Retirement Fund - The 40s Plan Direct-Growth | 50774 | 3.15% | -1.68% | -2.08% | Apr 2025 | |
 WhiteOak Capital Pharma and Healthcare Fund Direct - Growth | 0 | 0.00% | -0.86% | -0.61% | Apr 2025 | |
 UTI Small Cap Fund Direct - Growth | 0 | 0.00% | -0.85% | -0.83% | Apr 2025 | |
 Invesco India Large & Mid Cap Fund Direct-Growth | 2120957 | 2.18% | -0.33% | -0.29% | Apr 2025 | |
| Invesco India Mid Cap Fund Direct-Growth | 2000728 | 2.31% | -0.32% | -0.32% | Apr 2025 | |
| Invesco India Smallcap Fund Direct - Growth | 1754083 | 1.97% | 0.26% | 0.25% | Apr 2025 | |
 Mirae Asset Small Cap Fund Direct-Growth | 333300 | 1.68% | 0.25% | 0.13% | Apr 2025 | |
 Kotak Healthcare Fund Direct - Growth | 150000 | 2.52% | -0.25% | -0.68% | Apr 2025 | |
 Edelweiss Recently Listed IPO Fund Direct-Growth | 300000 | 2.48% | -0.25% | 0.16% | Apr 2025 | |
| Invesco India Business Cycle Fund Direct-Growth | 161233 | 3.74% | -0.24% | -0.19% | Apr 2025 | |
| Mirae Asset Healthcare Fund Direct - Growth | 881569 | 2.29% | -0.22% | -0.21% | Apr 2025 | |
 DSP Healthcare Fund Direct - Growth | 1597108 | 3.82% | -0.21% | 0.09% | Apr 2025 | |
| Aditya Birla Sun Life Pharma & Healthcare Fund Direct-Growth | 254988 | 2.17% | -0.21% | -0.16% | Apr 2025 | |
 ITI Pharma and Healthcare Fund Direct - Growth | 26626 | 0.85% | -0.21% | -0.17% | Apr 2025 | |
| UTI Healthcare Fund Direct-Growth | 170057 | 1.14% | -0.20% | -0.29% | Apr 2025 | |
 Mahindra Manulife Multi Cap Fund Direct - Growth | 1048287 | 1.43% | -0.20% | -0.20% | Apr 2025 | |
| Invesco India Flexi Cap Fund Direct - Growth | 569917 | 1.44% | 0.19% | 0.20% | Apr 2025 | |
 PGIM India Retirement Fund Direct - Growth | 13155 | 1.14% | -0.18% | -0.23% | Apr 2025 | |
 HSBC Multi Cap Fund Direct - Growth | 753650 | 1.17% | -0.17% | -0.17% | Apr 2025 | |
| HSBC Large and Mid Cap Fund Direct - Growth | 597062 | 1.07% | -0.14% | -0.12% | Apr 2025 | |
 Nippon India Pharma Fund Direct-Growth | 1430423 | 1.21% | -0.14% | -0.01% | Apr 2025 | |
| Kotak Manufacture in India Fund Direct - Growth | 381304 | 1.15% | -0.13% | -0.14% | Apr 2025 | |
 HDFC Pharma And Healthcare Fund Direct - Growth | 254443 | 1.06% | -0.12% | -0.14% | Apr 2025 | |
| PGIM India Healthcare Fund Direct-Growth | 14574 | 0.94% | -0.12% | -0.10% | Apr 2025 | |
| PGIM India Small Cap Fund Direct - Growth | 205433 | 1.02% | -0.12% | -0.09% | Apr 2025 |
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
